Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail

Ying Huang¹, Yun Guo¹, Yi Xu¹, Fei Liu² and Suli Dai²

¹The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China
²Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

ABSTRACT

Gastric cancer is one of the most common malignancies worldwide and has been identified as the third leading cause of cancer-related mortality. Flotillin-1 is a lipid raft-associated scaffolding protein and plays an important role in the progression and development of several malignant carcinomas. Flotillin-1 is involved in epithelial-mesenchymal transition (EMT) process of several solid tumors to promote metastasis. However, the detailed characteristics and mechanisms of Flotillin-1 in gastric cancer have rarely been investigated. In this study, we found Flotillin-1 upregulated in gastric cancer, and the high expression of Flotillin-1 correlated with a worse prognosis. The migration and invasion ability of gastric cancer cells was upregulated by overexpressing Flotillin-1. Knockdown of Flotillin-1 inhibits gastric cancer cells metastasis. Flotillin-1 is a key regulator of EMT process and promotes gastric cancer cells metastasis through inducing EMT. Flotillin-1 may interact with a deubiquitinase to inhibit the ubiquitination of Snail in gastric cancer cells to promote EMT process. Our study provides a rationale and potential target for the treatment of gastric cancer.

INTRODUCTION

Gastric cancer is one of the most common malignancies worldwide and has been identified as the third leading cause of cancer-related mortality, with 1,089,103 newly diagnosed cases and 768,793 deaths in 2020 (Sung et al., 2021). Early detection and curative resection resulted in improved outcomes for patients with early gastric cancer, but the prognosis for the advanced patients remains poor, the five-year survival rate is less than 40% (Allemani et al., 2018). The main cause of death in advanced gastric cancer patients is metastasis. In the past two decades, the proportion of patients with metastatic gastric cancer has risen to more than 40% (Bernards et al., 2013; Thomassen et al., 2014; Riihimaki et al., 2016). Thus, it is necessary to study the molecular mechanism of gastric cancer metastasis to elucidate its pathogenesis.

Epithelial-mesenchymal transition (EMT) is an evolutionarily conserved developmental program that is associated with cancer development and confers metastasis properties to cancer cells by enhancing their mobility and invasiveness (Mittal, 2018). Cancer cells in primary tumors lose intercellular adhesion mediated by E-cadherin inhibition, break through the basement membrane with increased invasive properties, enter the bloodstream...
through intravasation, and exit the bloodstream to form micro-metastases (Lindsey & Langhans, 2014; Lambert, Pattabiraman & Weinberg, 2017). EMT is a cellular process in which epithelial cells lose their epithelial phenotypes and acquire mesenchymal-like characteristics. The initiation of metastasis requires invasion, which is achieved through EMT (Singh et al., 2018). Several signaling pathways have been implicated to be involved in EMT, including TGF-β, Wnt/beta-catenin and Notch, mediating the loss of the epithelial marker E-cadherin and the gain of the expression of the mesenchymal marker N-cadherin and Vimentin (Gonzalez & Medici, 2014; Zhang, Tian & Xing, 2016; Brabletz et al., 2018).

Flotillin-1 is a lipid raft-associated scaffolding protein and it is implicated in a variety of cellular processes including axonal regeneration, cellular adhesion, endocytosis, phagocytosis and signal transduction (Langhorst, Reuter & Stuermer, 2005). In addition, Flotillin-1 plays an important role in the progression and development of several malignant carcinomas (Gauthier-Rouviere et al., 2020). Upregulation of Flotillin-1 predicts poor prognosis and promotes malignant progression, proliferation and metastasis of multiple tumors, including non-small cell lung, breast cancer, renal cell carcinoma, neuroblastoma, bladder cancer, prostate cancer and hepatocellular carcinoma (Li et al., 2014a; Lin et al., 2011; Zhang et al., 2014; Tomiyama et al., 2014; Guan et al., 2014; Jang et al., 2019; Zhang et al., 2013). In particular, studies shown that Flotillin-1 is involved in EMT process of several solid tumors to promote metastasis. In cervical cancer, Flotillin-1 facilitates cell metastasis through Wnt/beta-catenin and NF-κB pathway-regulated EMT (Li et al., 2016). Flotillin-1 promotes cell invasion and migration by inducing EMT and modulating the cell cycle in lung adenocarcinoma (Zhao et al., 2018). However, the detailed characteristics and mechanisms of Flotillin-1 in gastric cancer have rarely been investigated.

In this study, we determined the role of Flotillin-1 in the metastasis process of gastric cancer and molecular mechanisms of Flotillin-1 in the regulation of EMT.

**MATERIALS AND METHODS**

**Cell culture**

The human gastric cancer cell line SGC-7901 was obtained from GeneChem (Shanghai, China), AGS was acquired from the Shanghai Institute for Biological Science. Both of the cell lines were cultured in RPMI/1640 medium (Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Waltham, MA, USA) and incubated at 37 °C with 5% CO2. HEK293T cell were purchased from American Type Culture Collection (ATCC) and grown in DMEM medium (Gibco, Waltham, MA, USA) plus with 10% FBS.

**Plasmids and antibodies**

Flotillin-1 and Snail were inserted into the pLVX vector. The Flotillin-1 shRNA sequences were cloned into the pSIH vector. The sequences of shRNAs are shown in Table S1.

Antibodies used in this study: anti-Flotillin-1 (#18634; Cell Signaling Technology, Danvers, MA, USA), anti-Snail (#3879; Cell Signaling Technology, Danvers, MA, USA), anti-E-cadherin (#3195; Cell Signaling Technology, Danvers, MA, USA), anti-N-cadherin (#13116; Cell Signaling Technology, Danvers, MA, USA), anti-Vimentin (#5741; Cell Signaling Technology, Danvers, MA, USA), anti-β-actin (A5441; Sigma-Aldrich, USA),
anti-Flag (#14793; Cell Signaling Technology, Danvers, MA, USA), anti-HA (sc-53516; Santa Cruz Biotechnology, Dallas, TX, USA), Goat anti-Rabbit IgG (AS014; ABclonal, Hubei, China), Goat anti-mouse IgG (AS003; ABclonal, Hubei, China).

**Generation of stable transfected cells**
The stable transfected cells including Flotillin-1-overexpressing and -knockdown were generated by lentivirus. The lentivirus was generated using packaging vectors PSPAX2, pMD2G and Flotillin-1-overexpressing plasmid or Flotillin-1-shRNA plasmid. SGC-7901 and AGS cells were infected with indicated lentivirus and performed the stable transfected cell screening using puromycin. The third generation of stable transfected cells were used for subsequent experiments.

**Quantitative real-time PCR (qRT-PCR)**
Total RNA was extracted from cells using TRIzol reagent and cDNA was prepared from total RNA using the Quantscript RT Kit following manufacturer’s instruction. qRT-PCR assay was performed using SYBR Green Mix following the manufacturer’s instruction. The primers used in qRT-PCR were shown in Table S2.

**Immunoblotting assay**
Cells were lysed by RIPA lysis buffer plus a cocktail of protease inhibitor. The protein concentration was detected using Bicinchoninic acid (BCA) assay. Total proteins (10 µg for each well) were separated by SDS-PAGE gel and transferred to Polyvinylidene difluoride (PVDF) membranes. The membrane was blocked with 5% fat-free milk for 1 h and incubated with primary antibodies overnight. Next day, the membrane was incubated with conjugated secondary antibody. The protein signal was visualized using ECL detection reagents.

**Migration and invasion assay**
Cell migration and invasion assay were performed using 24-well Transwell plate with or without coated Matrigel. Cells (5 × 10⁴ for each well) were plated into Boyden chambers with serum-free media. Media containing 10% FBS were added into the bottom chambers, and the cells were cultured for 24 h at 37 °C with 5% CO₂. Finally, the cells were fixed by methanol and stained with crystal violet.

**Wound healing assay**
Cells (2 × 10⁵ for each well) were plated into 6-well plates and scratched using a sterile pipette tip. The cells were washed with phosphate-buffered saline (PBS) and incubated in media containing 2% FBS. Images were obtained at 0, 24, 48, 72 h.

**Immunoprecipitation assay**
Cells were treated with 20 µg/ml MG132 for 6 h and lysed with RIPA lysis buffer plus a cocktail of protease inhibitor. For Flag-tagged proteins, cell lysates were incubated with anti-Flag M2 magnetic beads overnight. Finally, the immunoprecipitates were subjected to immunoblotting.
**Ubiquitination assay**
For ubiquitination assay, the cells were treated with MG132 for 6 h and lysed using RIPA lysis buffer plus a cocktail of protease inhibitor. The cell lysates were incubated with anti-Flag M2 magnetic beads overnight. The ubiquitin level of Flag-Snail was detected with anti-HA antibody.

**Protein degradation analysis**
For Snail protein degradation analysis, cells were treated with cycloheximide (CHX, 50 µg/ml) for 1, 2 h. The protein level of Snail was detected using immunoblotting assay.

**Statistical analysis**
Survival analysis was analyzed using a two-sided log-rank test, others were analyzed using unpaired t-test. Except for special instructions, all results were shown as mean ± SEM of three independent experiments. All statistical analyses were performed with Graphpad Prism. A p < 0.05 was considered significant.

**RESULTS**

**Increased Flotillin-1 predicts a poor prognosis of gastric cancer patients**
To identify the effect of Flotillin-1 expression level on the clinical prognosis of gastric cancer, we analyzed the data from The Cancer Genome Atlas (TCGA). A Flotillin-1 amplification occurs in several solid tumors including gastric cancer (Fig. 1A). Compared to normal tissues, the expression level of Flotillin-1 was significantly higher in gastric cancer samples (Fig. 1B). Gastric cancer patients with high Flotillin-1 expression level correlated with a worse survival overall survival, advanced TNM stage and distant metastasis (Figs. 1C–1E). Together, those results shown that Flotillin-1 can participate in the development of gastric cancer.

**Overexpression of Flotillin-1 promotes gastric cancer metastasis**
To identify the function of Flotillin-1 in gastric cancer, we overexpressed Flotillin-1 in two gastric cancer cell lines SGC-7901 and AGS. The overexpression efficiency was confirmed by qRT-PCR and immunoblotting (Figs. 2A–2D). To examine the role of Flotillin-1 in gastric cancer metastasis, we performed Transwell and wound healing assays to detect the abilities of migration and invasion. Overexpression of Flotillin-1 not only promoted the migration and invasion of SGC-7901 cells, but also increased the wound healing ability of gastric cancer cells (Figs. 2E–2F). In addition, we obtained the same results in AGS cells (Figs. 2G–2H). Taken together, the results show that overexpression of Flotillin-1 promotes gastric cancer cell migration and invasion and suggested that Flotillin-1 might have a role in cancer metastasis.

**Knockdown of Flotillin-1 inhibits gastric cancer metastasis**
To further study the role of Flotillin-1 in gastric cancer metastasis, we knocked down Flotillin-1 in SGC-7901 and AGS cells using shRNA. The knockdown efficiency was confirmed by qRT-PCR and immunoblotting (Figs. 3A–3D). We performed Transwell
Figure 1  Increased Flotillin-1 predicts a poor prognosis of gastric cancer patients. (A) A histogram shows the amplification frequency of Flotillin in 23 tumor types. The data were taken from TCGA Pan-Cancer Atlas studies. (B) The expression of Flotillin-1 in gastric cancer tissues and normal samples. T represents tumor tissues (n = 408), N represents normal tissues (n = 36). (C) Kaplan-Meier plot showing the overall survival of 875 gastric cancer patients stratified by Flotillin-1 expression level. (D–E) Comparison between the proportion of gastric cancer patients with different Flotillin-1 expression level in T stage (D) and distant metastasis (E). *p < 0.05, **p < 0.01, p value was calculated with t test, except survival analysis was analyzed using a two-sided log-rank test.

Huang et al. (2022), PeerJ, DOI 10.7717/peerj.13901/fig-1

and wound healing assays to detect the cell migration and invasion abilities of Flotillin-1-knockdown and control gastric cancer cells. As expected, knockdown of Flotillin-1 inhibited the migration, invasion and wound healing abilities of SGC-7901 and AGS cells (Figs. 3E–3H). Thus, the results show that knockdown of Flotillin-1 inhibits gastric cancer cell migration and invasion and suggested that Flotillin-1 might have a role in cancer metastasis.

Flotillin-1 promotes gastric cancer metastasis through inducing EMT

The initiation of metastasis requires invasion, which is achieved through EMT. To identify whether Flotillin-1 promotes gastric cancer metastasis through EMT process. We detected the expression of several EMT markers including epithelial marker E-cadherin and mesenchymal markers N-cadherin, Vimentin and Snail. Overexpression of Flotillin-1
Figure 2 Overexpression of Flotillin-1 promotes gastric cancer metastasis. (A–B) The mRNA (A) and protein (B) levels of Flotillin-1 in SGC-7901 cells overexpressing Flotillin-1. (C–D) The mRNA (C) and protein (D) levels of Flotillin-1 in AGS cells overexpressing Flotillin-1. (E) The migration and invasion abilities of SGC-7901 cells overexpressing Flotillin-1 were detected by Transwell assay. Scale bars, 500 µm. (F) The migration ability of SGC-7901 cells overexpressing Flotillin-1 was examined by wound healing assay. Scale bars, 500 µm. (G) The migration and invasion abilities of AGS cells overexpressing Flotillin-1 were detected by Transwell assay. Scale bars, 500 µm. (H) The migration ability of SGC-7901 cells overexpressing Flotillin-1 was examined by wound healing assay. Scale bars, 500 µm. **p < 0.01, ***p < 0.001, ****p < 0.0001, p value was calculated with t test, compared to control group. All results were shown as mean ± SEM of three independent experiments.
Figure 3  Knockdown of Flotillin-1 inhibits gastric cancer metastasis. (A–B) The mRNA (A) and protein (B) levels of Flotillin-1 in Flotillin-1-knockdown (using shRNA targeting Flotillin-1 including shFlotillin-1-1 and shFlotillin-1-2) SGC-7901 cells. (C–D) The mRNA (left) and protein (right) levels of Flotillin-1 in Flotillin-1-knockdown AGS cells. (E) The migration and invasion abilities of Flotillin-1-knockdown SGC-7901 cells were detected by Transwell assay. Scale bars, 500 µm. (F) The migration ability of Flotillin-1-knockdown SGC-7901 cells was examined by wound healing assay. Scale bars, 500 µm. (G) The migration and invasion abilities of Flotillin-1-knockdown AGS cells were detected by Transwell assay. Scale bars, 500 µm. (H) The migration ability of Flotillin-1-knockdown AGS cells was examined by wound healing assay. Scale bars, 500 µm. **p < 0.01, ***p < 0.001, ****p < 0.0001, p value was calculated with t test, compared to control group. All results were shown as mean ± SEM of three independent experiments.
Flotillin-1 promotes gastric cancer metastasis through inducing EMT. (A–B) The protein expression levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1 overexpressing SGC-7901 (A) and AGS (B) cells. (C–D) The mRNA levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1 overexpressing SGC-7901 (C) and AGS (D) cells. (E–F) The protein expression levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1-knockdown SGC-7901 (E) and AGS (F) cells. (G–H) The mRNA levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1-knockdown SGC-7901 (G) and AGS (H) cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, p value was calculated with t test, compared to control group. All results were shown as mean ± SEM of three independent experiments.

Huang et al. (2022), PeerJ, DOI 10.7717/peerj.13901

Figure 4  Flotillin-1 promotes gastric cancer metastasis through inducing EMT. (A–B) The protein expression levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1 overexpressing SGC-7901 (A) and AGS (B) cells. (C–D) The mRNA levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1 overexpressing SGC-7901 (C) and AGS (D) cells. (E–F) The protein expression levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1-knockdown SGC-7901 (E) and AGS (F) cells. (G–H) The mRNA levels of E-cadherin, N-cadherin, Vimentin and Snail in Flotillin-1-knockdown SGC-7901 (G) and AGS (H) cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, p value was calculated with t test, compared to control group. All results were shown as mean ± SEM of three independent experiments.

Huang et al. (2022), PeerJ, DOI 10.7717/peerj.13901

Downregulated the protein and mRNA levels of E-cadherin, and upregulated the N-cadherin, Vimentin and Snail levels (Figs. 4A–4D). In contrast, knockdown of Flotillin-1 increased the expression of E-cadherin and inhibited the expression of N-cadherin, Vimentin and Snail (Figs. 4E–4H). Moreover, we found that Flotillin-1 regulated the protein level of Snail, but has no effect on the mRNA level. Taken together, those results determined that Flotillin-1 promotes the EMT process in gastric cancer cells.
Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail

Snail, as an EMT-transcription factor, has been confirmed to play an integral role throughout EMT of all types. In addition, Snail is a labile protein and degraded by ubiquitin-proteasome system, and Flotillin-1 regulates the protein expression of Snail but no effect on mRNA level. Thus, we speculated that Flotillin-1 promoted the EMT process through increasing the protein stability of Snail. To identify the hypothesis, we performed immunoprecipitation and ubiquitination assays. As expected, Flotillin-1 interacted with Snail (Fig. 5A) and decreased the ubiquitination level of Snail (Fig. 5B). In addition, Flotillin-1 inhibited the degradation of Snail in gastric cancer cells (Figs. 5C–5D). Taken together, the results shown that Flotillin-1 decreased the ubiquitination level of Snail and inhibited its degradation.
DISCUSSION

Flotillin-1, a lipid raft protein, is involved in cell migration and invasion, cell signaling, proliferation, differentiation and endocytosis (Langhorst, Reuter & Stuermer, 2005; Affentranger et al., 2011; Guillaume et al., 2013; Otto & Nichols, 2011). More studies have shown that Flotillin-1 plays an important role in the development of malignant tumors and may act as a prognosis factor in solid carcinomas (Li et al., 2014b; Liu et al., 2018). The upregulated expression of Flotillin-1 was associated with tumor cell progression and poor prognosis in hepatocellular carcinoma (Zhang et al., 2013). Knockdown of Flotillin-1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a (Lin et al., 2011). MiR-214-3p inhibited cell proliferation and metastasis in hepatocellular carcinoma by downregulating Flotillin-1 (Liu et al., 2019). In tongue squamous cell cancer, the expression of Flotillin-1 was correlated with pathological stage, depth of invasiveness, lymph node metastasis, recurrence and shorter survival (Li et al., 2014b). In this study, we found Flotillin-1 upregulated in gastric cancer, and the high expression of Flotillin-1 correlated with a worse prognosis. In addition, the migration and invasion ability of gastric cancer cells was upregulated by overexpressing Flotillin-1. Knockdown of Flotillin-1 inhibited the cell metastasis in gastric cancer. Therefore, our results demonstrate Flotillin-1 participates in the development of gastric cancer, especially in promoting metastasis.

EMT is a process by which epithelial cells lose their apical-basal polarity and intercellular adhesion properties and transform into invasive mesenchymal cells, all of which provide conditions for the invasion and metastasis of cancer cells (Taylor, Parvani & Schiemann, 2010; Pearlman et al., 2017; Brabletz et al., 2021; Blackley et al., 2021). There are numerous inducers of EMT, and the determinant inducers corresponding to different sites of tumors will be the key to the targeted therapy. In this study, we identified that overexpression of Flotillin-1 decreased the epithelial marker E-cadherin and upregulated mesenchymal markers such as N-cadherin, Vimentin and Snail in gastric cancer cells. E-cadherin was upregulated, and N-cadherin, Vimentin and Snail were decreased in Flotillin-1-knockdown gastric cancer cells. Therefore, our study demonstrates that Flotillin-1 can participate in EMT process and promotes gastric cancer metastasis through inducing EMT.

Snail is a zinc-finger transcription factor that regulates EMT during mesoderm and neural crest development (Wu & Zhou, 2010). In breast cancer, Snail expression has been shown to be upregulated in recurrent tumors (Wang et al., 2013). In addition, it is associated with reduced metastasis and recurrence-free survival. Similar to zinc finger E-box-binding homeobox 1 (ZEB1), Snail represses cadherin 1 (CDH1) transcription by binding to the E-box in the CDH1 promoter (Serrano-Gomez, Maziveyi & Alahari, 2016). It also regulates CDH1 expression in concert with histone methyltransferases (HMT) and DNA methyltransferases (DNMTs) (Skrypek et al., 2017). Snail interacts directly with the E-cadherin promoter, recruiting histone deacetylase 1 (HDAC1), HDAC2 and co-repressor Sin3A to the CDH1 promoter and silencing their expression through deacetylation of histones H3 and H4 (Peinado et al., 2004). Snail comprehensively affects the expression profile of epithelial cells, besides E-cadherin, it also downregulates claudin, occludin, mucin,
vimentin, fibronectin and matrix metalloproteinases (Ohkubo & Ozawa, 2004). Thus, the role of Snail is mainly to downregulate epithelial markers and upregulate mesenchymal markers, and the increased expression of matrix metalloproteinases it regulates makes the cells migratory. In addition, Snail is a labile protein and degraded by ubiquitin-proteasome system. In our study, we demonstrate the interaction between Flotillin-1 and Snail. The protein expression of Snail is upregulated by overexpressing Flotillin-1, and overexpression of Flotillin-1 delays the degradation of Snail in gastric cancer cells. The ubiquitination level of Snail is downregulated in gastric cancer cells overexpressing Flotillin-1. Therefore, Flotillin-1 may interact with a deubiquitinase to inhibit the ubiquitination of Snail in gastric cancer to promote EMT process. This is a direction of our further study.

In summary, our study demonstrate Flotillin-1 can participate in the development of gastric cancer, and promotes gastric cancer metastasis. Increased Flotillin-1 predicts a poor prognosis of gastric cancer patients. Flotillin-1 promotes gastric cancer metastasis through inducing EMT, and promotes EMT of gastric cancer via stabilizing Snail. Our study provides a rationale and potential target for the treatment of gastric cancer.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
This study was supported by the Medical Science Research Project of Hebei Province (20220202). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**
The following grant information was disclosed by the authors:
Medical Science Research Project of Hebei Province: 20220202.

**Competing Interests**
The authors declare there are no competing interests.

**Author Contributions**
- Ying Huang conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Yun Guo performed the experiments, prepared figures and/or tables, and approved the final draft.
- Yi Xu performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Fei Liu analyzed the data, prepared figures and/or tables, and approved the final draft.
- Suli Dai analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

**Data Availability**
The following information was supplied regarding data availability:
The raw data are available in the Supplemental Files.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.13901#supplemental-information.

REFERENCES

Affentranger S, Martinelli S, Hahn J, Rossy J, Niggli V. 2011. Dynamic reorganization of flotillins in chemokine-stimulated human T-lymphocytes. *BMC Cell Biology* **12**:28 DOI 10.1186/1471-2121-12-28.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Silva GAE, Chen W-Q, Eser S, Engholm G, Stiller CA, Morales-Espejel V, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP. 2018. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet* **391**(10125):1023–1075 DOI 10.1016/S0140-6736(17)33326-3.

Bernards N, Creemers GJ, Nieuwenhuijzen GAP, Bosscha K, Prijn JFM, Lemmens VEPP. 2013. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. *Annals of Oncology* **24**(12):3056–3060 DOI 10.1093/annonc/mdt401.

Blackley DG, Cooper JH, Pokorska P, Ratheesh A. 2021. Mechanics of developmental migration. *Seminars in Cell and Developmental Biology* **120**:66–74 DOI 10.1016/j.semcdb.2021.07.002.

Brabletz T, Kalluri R, Nieto MA, Weinberg RA. 2018. EMT in cancer. *Nature Reviews Cancer* **18**(2):128–134 DOI 10.1038/nrc.2017.118.

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. 2021. Dynamic EMT: a multi-tool for tumor progression. *The EMBO Journal* **40**(18):e108647.

Gauthier-Rouviere C, Bodin S, Comunale F, Planchon D. 2020. Flotillin membrane domains in cancer. *Cancer and Metastasis Reviews* **39**(2):361–374 DOI 10.1007/s10555-020-09873-y.

Gonzalez DM, Medici D. 2014. Signaling mechanisms of the epithelial-mesenchymal transition. *Science Signaling* **7**(344):re8 DOI 10.1126/scisignal.2005189.

Guan Y, Song H, Zhang G, Ai X. 2014. Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. *Oncology Reports* **32**(2):748–754 DOI 10.3892/or.2014.3221.

Guillaume E, Comunale F, Khoa ND, Planchon D, Bodin S, Gauthier-Rouvière C. 2013. Flotillin microdomains stabilize cadherins at cell–cell junctions. *Journal of Cell Science* **126**(Pt 22):5293–5304.

Jang D, Kwon H, Choi M, Lee J, Pak Y. 2019. Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation. *Oncogene* **38**(17):3248–3260 DOI 10.1038/s41388-018-0641-1.

Lambert AW, Pattabiraman DR, Weinberg RA. 2017. Emerging biological principles of metastasis. *Cell* **168**(4):670–691 DOI 10.1016/j.cell.2016.11.037.
Langhorst MF, Reuter A, Stuermer CA. 2005. Scaffolding microdomains and beyond: the function of reggie/flotillin proteins. *Cellular and Molecular Life Sciences* 62(19–20):2228–2240 DOI 10.1007/s00018-005-5166-4.

Li H, Wang R-M, Liu S-G, Zhang J-P, Luo J-Y, Zhang B-J, Zhang X-G. 2014a. Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer. *Tumor Biology* 35(4):3311–3315 DOI 10.1007/s13277-013-1434-3.

Li Z, Yang Y, Gao Y, Wu X, Yang X, Zhu Y, Yang H, Wu L, Yang C, Song L. 2016. Elevated expression of flotillin-1 is associated with lymph node metastasis and poor prognosis in early-stage cervical cancer. *American Journal of Cancer Research* 6(1):38–50.

Li H, Zhang Y, Chen S-W, Li F-J, Zhuang S-M, Wang L-P, Zhang J, Song M. 2014b. Prognostic significance of Flotillin1 expression in clinically N0 tongue squamous cell cancer. *International Journal of Clinical and Experimental Pathology* 7(3):996–1003.

Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L. 2011. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. *Clinical Cancer Research* 17(10):3089–3099 DOI 10.1158/1078-0432.CCR-10-3068.

Lindsey S, Langhans SA. 2014. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. *Frontiers in Oncology* 4:358 DOI 10.3389/onc.2014.00358.

Otto GP, Nichols BJ. 2011. The roles of flotillin microdomains–endocytosis and beyond. *Journal of Cell Science* 124(Pt 23):3933–3940 DOI 10.1242/jcs.092015.

Pearlman RL, Oca MKMD, Pal HC, Afaq F. 2017. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. *Cancer Letters* 391:125–140 DOI 10.1016/j.canlet.2017.01.029.

Peinado H, Ballestar E, Esteller M, Cano A. 2004. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. *Molecular and Cellular Biology* 24(1):306–319 DOI 10.1128/MCB.24.1.306–319.2004.

Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. 2016. Metastatic spread in patients with gastric cancer. *Oncotarget* 7(32):52307–52316 DOI 10.18632/oncotarget.10740.
Serrano-Gomez SJ, Maziveyi M, Alahari SK. 2016. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. *Molecular Cancer* 15:18 DOI 10.1186/s12943-016-0502-x.

Singh M, Yelle N, Venugopal C, Singh SK. 2018. EMT: mechanisms and therapeutic implications. *Pharmacology & Therapeutics* 182:80–94 DOI 10.1016/j.pharmthera.2017.08.009.

Skrypek N, Goossens S, Smedt ED, Vandamme N, Berx G. 2017. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity. *Trend in Genetics* 33(12):943–959 DOI 10.1016/j.tig.2017.08.004.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *A Cancer Journal for Clinicians* 71(3):209–249 DOI 10.3322/caac.21660.

Taylor MA, Parvani JG, Schiemann WP. 2010. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. *Journal of Mammary Gland Biology and Neoplasia* 15(2):169–190 DOI 10.1007/s10911-010-9181-1.

Thomassen I, Van Gestel YR, Van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, De Hingh IH. 2014. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. *International Journal of Cancer* 134(3):622–628 DOI 10.1002/ijc.28373.

Tomiyama A, Uekita T, Kamata R, Sasaki K, Takita J, Ohira M, Nakagawara A, Kitanaka C, Mori K, Yamaguchi H, Sakai R. 2014. Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association. *Cancer Research* 74(14):3790–3801.

Wang Y, Shi J, Chai K, Ying X, Zhou BP. 2013. The role of snail in EMT and tumorigenesis. *Current Cancer Drug Targets* 13(9):963–972 DOI 10.2174/15680096113136660102.

Wu Y, Zhou BP. 2010. Snail: more than EMT. *Cell Adhesion & Migration* 4(2):199–203 DOI 10.4161/cam.4.2.10943.

Zhang Y, Li J, Song Y, Chen F, Pei Y, Yao F. 2014. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival. *Molecular Medicine Reports* 10(2):860–866 DOI 10.3892/mmr.2014.2310.

Zhang J, Tian XJ, Xing J. 2016. Signal transduction pathways of EMT induced by TGF-beta, SHH, and WNT and their crosstalks. *Journal of Clinical Medicine* 5(4):41 DOI 10.3390/jcm5040041.

Zhang SH, Wang C-J, Shi L, Li X-H, Zhou J, Song L-B, Liao W-T. 2013. High expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. *PLOS ONE* 8(6):e64709 DOI 10.1371/journal.pone.0064709.

Zhao L, Li J, Liu Y, Zhou W, Shan Y, Fan X, Zhou X, Shan B, Song Y, Zhan Q. 2018. Flotillin1 promotes EMT of human small cell lung cancer via TGF-beta signaling pathway. *Cancer Biology & Medicine* 15(4):400–414 DOI 10.20892/j.issn.2095-3941.2018.0053.